DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

ADDRESS AND PHONE NUMBER
12420 Parklawn Drive, Room 2032
Rockville, MD 20857

DATE(S) OF INSPECTION
6/13/2019-6/21/2019

FIR NUMBER
3006549835

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Shailesh N. Patel, Vice President

FIRM NAME
Dr. Reddy's Laboratories Ltd.

STREET ADDRESS
P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada

CITY, STATE, ZIP CODE, COUNTRY
Visakhapatnam, Andhra Pradesh, 530046
India

TYPE OF ESTABLISHMENT INSPECTED
Manufacturer

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1
Acceptance criteria were not established prior to the performance of validation activities.

Specifically, is not clear how your firm determined the acceptance criteria for the Functionality Testing (Break loose force & Glide force) conducted as part of finished product release specification for Injection 0.1 mL.

For example, your firm explained that the worst-case condition was considered for the applied injection based on the container size as part of the criteria to test the samples. Your data was only obtained for the samples from stability study for 24 months for (Batches: ) as reference data for Break loose force of ( ) Newton and Glide force of ( ) Newton.

However, your firm established the test limit for Break loose force as ( ) Newton and for Glide force as ( ) Newton as the finished product release specification test limits. This was not supported by scientific data that demonstrated the impact to the end user or to the finished product functionality.

OBSERVATION 2
The device design was not correctly translated into production specifications.

Specifically, your Acceptance Quality Limit [AQL] does not take into account the component critical dimensions specification during receipt of components for the manufacture of Injection 0.1 mL such as and stoppers.

SEE REVERSE OF THIS PAGE
Farhana Khan, Investigator
Monica C Burgos Garcia, Investigator

DATE ISSUED
8/21/2019

FORM FDA 483 (69/80)
INSPECTIONAL OBSERVATIONS
PAGE 1 of 3 PAGES
## DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

<table>
<thead>
<tr>
<th>DISTRICT ADDRESS AND PHONE NUMBER</th>
<th>DATE(S) OF INSPECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>12420 Parklawn Drive, Room 2032</td>
<td>6/13/2019-6/21/2019*</td>
</tr>
<tr>
<td>Rockville, MD 20857</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FER NUMBER</td>
</tr>
<tr>
<td></td>
<td>3006549835</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shailesh N Patel, Vice President</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIRST NAME</th>
<th>STREET ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Reddy's Laboratories Ltd.</td>
<td>P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITY, STATE, ZIP CODE, COUNTRY</th>
<th>TYPE ESTABLISHMENT INSPECTED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visakhapatnam, Andhra Pradesh, 530046 India</td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

### DATES OF INSPECTION
6/13/2019(Thu), 6/14/2019(Fri), 6/17/2019(Mon), 6/18/2019(Tue), 6/19/2019(Wed), 6/20/2019(Thu), 6/21/2019(Fri)

---

SEE REVERSE OF THIS PAGE

<table>
<thead>
<tr>
<th>EMPLOYEE(S)' SIGNATURE</th>
<th>DATE ISSUED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Farhana Khan, Investigator</td>
<td>6/21/2019</td>
</tr>
<tr>
<td>Monica C Burgos Garcia, Investigator</td>
<td></td>
</tr>
</tbody>
</table>

FORM FDA 483 (09/08)  PREVIOUS EDITION CIRCULATED  INSPECTIONAL OBSERVATIONS  PAGE 2 of 3 PAGES
<table>
<thead>
<tr>
<th>District Address and Phone Number</th>
<th>Date of Inspection</th>
</tr>
</thead>
<tbody>
<tr>
<td>12420 Parklawn Drive, Room 2032</td>
<td>6/13/2019-6/21/2019*</td>
</tr>
<tr>
<td>Rockville, MD 20857</td>
<td>FR number: 3006549835</td>
</tr>
</tbody>
</table>

**Name and Title of Individual to Whom Report Issued**

Shailesh N Patel, Vice President

**Firm Name:**

Dr. Reddy's Laboratories Ltd.

**City, State, Zip Code, Country:**

Visakhapatnam, Andhra Pradesh, 530046 India

**Establishment Address:**

P1 - P9 Q1 - Q5, Phase III, VSEZ, Duvvada

**Type of Establishment Inspected:**

Manufacturer

**Annotations to Observations**

Observation 1: Promised to correct

Observation 2: Promised to correct

**See Reverse of This Page**

Farhana Khan, Investigator
Monica C Burgos Garcia, Investigator

**Date Signed:** 6/21/2019